Background: The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors.
Methods: We conducted a retrospective multi-institutional chart review of postoperative uterine cervical cancer patients with high-risk prognostic factors who had been treated with both 3DRT and weekly 40-mg/m cisplatin from 2007 to 2012. Each participating hospital provided detailed information regarding patient characteristics, treatment outcomes, and treatment complications.
Results: The eligible 96 patients were analyzed. The median follow-up period was 61 months. The 3-year relapse-free survival, overall survival (OS), and locoregional relapse-free survival (LRFS) rates were 76%, 90%, and 88%, respectively. In multivariate analysis, the histological finding of either adenocarcinoma or adenosquamous carcinoma was a significant risk factor for both OS and LRFS. The percentage of patients with grade ≥ 3 acute hematologic toxicity, acute lower gastrointestinal toxicity (GIT), and late lower GIT were 45%, 19%, and 17%, respectively.
Conclusions: The outcomes of concurrent chemoradiotherapy (CCRT) using weekly 40-mg/m cisplatin are similar to those in the previous studies that used several chemotherapy regimens. However, postoperative CCRT using 3DRT had a high level of late GIT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469659 | PMC |
| http://dx.doi.org/10.1007/s10147-018-01380-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hematologic Toxicity Profiles and the Impact of Hemoglobin Nadir and Transfusion on Oncologic Outcome in Definitive Radiochemotherapy for Cervical Cancer.
Cancers (Basel)
November 2024
Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
: Definitive radiochemotherapy with concomitant cisplatin 40 mg/m weekly represents the standard of care for locally advanced cervical cancer. Current studies (KEYNOTE-A18 and INTERLACE) are intensifying this regimen at the cost of increased hematologic toxicity. We aimed to evaluate influencing factors on hematotoxicity to ensure the safe application of radiochemotherapy.
View Article and Find Full Text PDFPattern of pelvic recurrence in MRI-only adaptive brachytherapy for locally advanced cervical cancer.
Brachytherapy
November 2024
Department of Oncology and Radiotherapy, University Hospital and Medical Faculty, Hradec Králové, Czech Republic.
Purpose: MRI-only adaptive brachytherapy (MRI-ABT) is the state-of-the-art for treating locally advanced cervical cancer (LACC) in combination with concurrent chemoradiotherapy. We aimed to evaluate the pattern of pelvic recurrence after the treatment.
Material And Methods: A total of one hundred LACC patients were treated between January 2017 and December 2023 with concurrent chemoradiotherapy of 45 Gy in 25 fractions ± boost to lymphadenopathy (up to a maximum dose of 60 Gy in 25 fractions) with concurrent weekly cisplatin chemotherapy at the dose of 40 mg/m/week, and MR-ABT.
Carbon-Ion Radiation therapy for Adenocarcinoma of the Uterine Cervix: Clinical Outcomes of a Multicenter Prospective Registry-Based Study in Japan (2016-2020).
Int J Radiat Oncol Biol Phys
October 2024
Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan. Electronic address:
Article Synopsis
- Cases of adenocarcinoma of the uterine cervix (AUC) have worse outcomes than squamous cell carcinoma, and this study examines carbon-ion radiation therapy (CIRT) for AUC through a nationwide Japanese registry in a multicenter prospective approach.
- The study included 42 patients with locally advanced untreated AUC who received CIRT and cisplatin, aiming to assess 2-year overall survival, local control, and disease-free survival rates, as well as late adverse events (AEs).
- Results showed a high 2-year overall survival rate of 97.5%, with local control at 80.9% and disease-free survival at 64.3%, indicating that CIRT is a promising treatment
Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial.
Cancer Immunol Immunother
October 2024
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.
Article Synopsis
- A phase I/II trial evaluated the safety and effectiveness of toripalimab alongside chemoradiotherapy for patients with locally advanced cervical squamous cell carcinoma.
- Twenty-two patients participated, receiving a combination of toripalimab and concurrent chemoradiotherapy, with a focus on safety and progression-free survival over two years.
- Results indicated a high objective response rate of 100%, with two-year progression-free survival at 81.8% and overall survival at 90.9%, demonstrating promising outcomes for this treatment combination.
Background: In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m) was non-inferior to 3-weekly cisplatin (100 mg/m) for postoperative high-risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose-limiting toxicity effect of cisplatin, affects overall survival (OS).
Methods: We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!